Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 09 2019
Historique:
received: 21 05 2019
accepted: 04 09 2019
entrez: 19 9 2019
pubmed: 19 9 2019
medline: 31 10 2020
Statut: epublish

Résumé

Preclinical models and clinical studies have shown that anti-CD20-based treatment has multifaceted consequences on T-cell immunity. We have performed a prospective study of peripheral T-cell compartment in FL patients, all exhibiting high tumor burden and receiving rituximab-chemotherapy-based regimen (R-CHOP). Before treatment, FL patients harbor low amounts of peripheral naive T cells, but high levels of CD4

Identifiants

pubmed: 31530876
doi: 10.1038/s41598-019-50029-y
pii: 10.1038/s41598-019-50029-y
pmc: PMC6748924
doi:

Substances chimiques

Biomarkers 0
R-CHOP protocol 0
Rituximab 4F4X42SYQ6
Vincristine 5J49Q6B70F
Doxorubicin 80168379AG
Cyclophosphamide 8N3DW7272P
Prednisone VB0R961HZT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13471

Références

Cell Rep. 2019 Feb 19;26(8):2178-2193.e3
pubmed: 30784598
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1926-30
pubmed: 12571354
Front Immunol. 2013 Dec 19;4:455
pubmed: 24391639
Curr Opin Oncol. 2010 Sep;22(5):424-30
pubmed: 20679770
Clin Rev Allergy Immunol. 2008 Feb;34(1):74-9
pubmed: 18240027
Lancet Oncol. 2018 Apr;19(4):549-561
pubmed: 29475724
J Immunol. 2014 Feb 15;192(4):1597-608
pubmed: 24453250
Clin Cancer Res. 2017 Jan 1;23(1):193-203
pubmed: 27354469
Blood. 2008 May 1;111(9):4764-70
pubmed: 18174380
J Exp Med. 1997 Nov 3;186(9):1407-18
pubmed: 9348298
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
pubmed: 15980149
Blood. 2005 Dec 1;106(12):3725-32
pubmed: 16123223
Br J Haematol. 2016 Oct;175(1):102-14
pubmed: 27341313
Leukemia. 2014 Sep;28(9):1872-84
pubmed: 24569779
Blood. 2013 Feb 21;121(8):1367-76
pubmed: 23297127
J Clin Oncol. 2009 Mar 20;27(9):1470-6
pubmed: 19224853
Semin Cancer Biol. 2014 Feb;24:23-32
pubmed: 23978491
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Clin Cancer Res. 2010 Jan 15;16(2):637-50
pubmed: 20068089
Blood. 2011 Apr 7;117(14):3836-46
pubmed: 21270444
N Engl J Med. 2004 Nov 18;351(21):2159-69
pubmed: 15548776
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97
pubmed: 17255259
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
Nat Rev Immunol. 2010 Apr;10(4):236-47
pubmed: 20224569
J Clin Oncol. 2006 Dec 1;24(34):5350-7
pubmed: 17135637
Blood. 2016 Aug 25;128(8):1112-20
pubmed: 27418643
Immunobiology. 2017 Apr;222(4):620-630
pubmed: 27986304
J Clin Oncol. 2007 Feb 1;25(4):390-8
pubmed: 17200149
J Clin Invest. 2012 Apr;122(4):1271-82
pubmed: 22426209
Clin Adv Hematol Oncol. 2012 Dec;10(12):810-8
pubmed: 23271353
Immun Ageing. 2008 Jul 25;5:6
pubmed: 18657274
Cell. 2015 May 21;161(5):1035-1045
pubmed: 25976835
Haematologica. 2009 Jan;94(1):70-7
pubmed: 19059937
Am J Hematol. 2018 Feb;93(2):296-305
pubmed: 29314206
Lancet. 2011 Jan 1;377(9759):42-51
pubmed: 21176949
N Engl J Med. 1993 Nov 25;329(22):1608-14
pubmed: 8232429
Hum Pathol. 2017 Jun;64:128-136
pubmed: 28414090
Front Immunol. 2017 Feb 14;8:146
pubmed: 28261208
J Immunol. 2014 Jul 15;193(2):746-56
pubmed: 24928986
Cancer Immunol Res. 2019 Mar;7(3):355-362
pubmed: 30659053
Clin Cancer Res. 2018 Feb 15;24(4):870-881
pubmed: 29217528
Blood. 2010 Aug 12;116(6):926-34
pubmed: 20439625
Blood. 2008 Jun 1;111(11):5359-70
pubmed: 18305220
Clin Cancer Res. 2011 Jun 15;17(12):4136-44
pubmed: 21518780
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Clin Cancer Res. 2012 May 15;18(10):2943-53
pubmed: 22407833
Leukemia. 2015 Apr;29(4):947-57
pubmed: 25231744
Front Immunol. 2017 Aug 14;8:950
pubmed: 28855903
Best Pract Res Clin Haematol. 2011 Jun;24(2):135-46
pubmed: 21658614
Blood Cancer J. 2015 Feb 20;5:e281
pubmed: 25700246

Auteurs

B Milcent (B)

Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.
Sorbonne Université, UMR-S 1138, Paris, 75006, France.
Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.

N Josseaume (N)

Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.
Sorbonne Université, UMR-S 1138, Paris, 75006, France.
Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.

F Petitprez (F)

Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.
Sorbonne Université, UMR-S 1138, Paris, 75006, France.
Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.
Ligue Nationale Contre le Cancer, Programme Cartes d'Identité des Tumeurs, Paris, 75014, France.

Q Riller (Q)

Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.
Sorbonne Université, UMR-S 1138, Paris, 75006, France.
Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.

S Amorim (S)

APHP, Saint-Louis Hospital, Hemato-oncology - Diderot University, Sorbonne Paris Cité, Paris, France.

P Loiseau (P)

Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.
Inserm UMR-S 1160, Paris, France.
Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, 7, France.

A Toubert (A)

Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.
Inserm UMR-S 1160, Paris, France.
Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, 7, France.

P Brice (P)

APHP, Saint-Louis Hospital, Hemato-oncology - Diderot University, Sorbonne Paris Cité, Paris, France.

C Thieblemont (C)

APHP, Saint-Louis Hospital, Hemato-oncology - Diderot University, Sorbonne Paris Cité, Paris, France.
EA7324 Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

J-L Teillaud (JL)

Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France.
Sorbonne Université, UMR-S 1138, Paris, 75006, France.
Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France.
Laboratory "Immune Microenvironment and Biotherapy", Sorbonne University UMRS1135, INSERM U.1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Paris, France.

S Sibéril (S)

Cordeliers Research Center-Inserm UMR-S 1138, "Cancer, Immune Control and Escape" Laboratory, Paris, 75006, France. sophie.siberil@sorbonne-universite.fr.
Sorbonne Université, UMR-S 1138, Paris, 75006, France. sophie.siberil@sorbonne-universite.fr.
Paris Descartes-Paris 5 University, UMR-S 1138, Paris, 75006, France. sophie.siberil@sorbonne-universite.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH